These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15228618)

  • 1. Effective use of TNF antagonists.
    Yocum D
    Arthritis Res Ther; 2004; 6 Suppl 2(Suppl 2):S24-30. PubMed ID: 15228618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologics in rheumatoid arthritis.
    Sharma PK; Hota D; Pandhi P
    J Assoc Physicians India; 2004 Mar; 52():231-6. PubMed ID: 15636315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?
    Schwartzman S; Fleischmann R; Morgan GJ
    Arthritis Res Ther; 2004; 6 Suppl 2(Suppl 2):S3-S11. PubMed ID: 15228615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
    Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recapitulation of the round-table discussion--assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis.
    Furst DE; Keystone E; Maini RN; Smolen JS
    Rheumatology (Oxford); 1999 Nov; 38 Suppl 2():50-3. PubMed ID: 10646494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.
    Genevay S; Finckh A; Ciurea A; Chamot AM; Kyburz D; Gabay C;
    Arthritis Rheum; 2007 May; 57(4):679-85. PubMed ID: 17471545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis.
    Haraoui B
    J Rheumatol Suppl; 2005 Jan; 72():46-7. PubMed ID: 15660467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic therapy for early rheumatoid arthritis: the latest evidence.
    Castro-Rueda H; Kavanaugh A
    Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Tijhuis GJ; van de Putte LB; Breedveld FC
    Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression in early rheumatoid arthritis.
    Combe B
    Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):59-69. PubMed ID: 19233046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing joint damage as the best measure of biologic drug therapy.
    Bresnihan B
    J Rheumatol Suppl; 2002 Sep; 65():39-43. PubMed ID: 12236622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics in rheumatoid arthritis.
    Ranganathan P
    Methods Mol Biol; 2008; 448():413-35. PubMed ID: 18370240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing treatment with biologics.
    Mader R; Keystone E
    J Rheumatol Suppl; 2007 Nov; 80():16-24. PubMed ID: 17985419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part I. Tumor necrosis factor alpha inhibitors].
    Swierkot J; Madej M
    Pol Merkur Lekarski; 2011 Apr; 30(178):283-8. PubMed ID: 21595176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy.
    Gonzalez-Gay MA; Gonzalez-Juanatey C; Vazquez-Rodriguez TR; Miranda-Filloy JA; Llorca J
    Ann N Y Acad Sci; 2010 Apr; 1193():153-9. PubMed ID: 20398022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies to control disease in rheumatoid arthritis with tumor necrosis factor antagonists-an opportunity to improve outcomes.
    Keystone EC
    Nat Clin Pract Rheumatol; 2006 Nov; 2(11):594-601. PubMed ID: 17075598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis.
    Wolfe F; Rasker JJ; Boers M; Wells GA; Michaud K
    Arthritis Rheum; 2007 Aug; 57(6):935-42. PubMed ID: 17665487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with rheumatoid arthritis].
    Merkesdal S; Ruof J
    Z Rheumatol; 2002; 61 Suppl 2():II/29-32. PubMed ID: 12491120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.